ASXL1 mutations are not limited to a specific molecular driver in MPN, with studies by Lasho et al. and McNamara et al. showing that, in accelerated and blast phase MPN, ASXL1 mutations are present in JAK2, CALR, MPL and triple negative disease [61,62]. Here, JAK2 is linked to myeloproliferative disorder.